Prescient Therapeutics LimitedASX: PTX

Prescient receives $3.4 million R&D Tax Refund

· Issued by Prescient Therapeutics Limited via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Prescient Therapeutics Limited has announced the receipt of a cash refund from the Australian Taxation Office under the R&D Tax Incentive program, which supports research and development activities. This funding follows a recent capital raise aimed at advancing the company's clinical studies.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Prescient receives $3.4 million R&D Tax Incentive refund Key Highlights: • Prescient Therapeutics (ASX:PTX) has received a cash refund of $3.4 million under the Australian Government's R&D Tax Incentive for the financial year ended 30 June 2026 • The non-dilutive refund adds to the $6 million...

Prescient Therapeutics Limited on 6ix

Earlier from Prescient Therapeutics

All Prescient Therapeutics news releases